phospholipase A and acyltransferase 3Genealiases: AdPLA · FPLD9 · H-REV107 · H-REV107-1 · HRASLS3 · HREV107
Q-omics provides the consensus-scored PLAAT3 profile across patient tissues and cancer cell-line models. PLAAT3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, PLAAT3 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, PLAAT3 RNA expression shows 17,404 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight PAAD, KIRC, and KIRP as cancer lineages where PLAAT3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PLAAT3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PLAAT3 survival associations across molecular data types. PLAAT3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PLAAT3 RNA expression–survival associations across cancer types. High PLAAT3 expression shows unfavorable associations in PAAD, LGG and UVM, but favorable associations in KIRP, THCA and SARC. The PAAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for PLAAT3 RNA expression.
This table summarizes PLAAT3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PLAAT3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PLAAT3 shows lower tumor expression in LUSC and BRCA and higher tumor expression in KIRC, COAD, THCA and STAD. The KIRC box plot shows higher PLAAT3 RNA expression in tumor versus normal tissue (log2 FC = +1.511, t-test p < 0.001).
This table shows molecular features associated with PLAAT3 in patient tissues and cancer cell lines. In patient samples, PLAAT3 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, PLAAT3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Lymphoma.
